^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Targretin gel (bexarotene topical)

    i
    Other names: Tarrexin gel, bexarotene gel, LGD 1069 topical, Targretyn gel
    Associations

    News

    Trials
    Company:
    Bausch Health, Eisai
    Drug class:
    Retinoid X receptor agonist
    Related drugs:
    Associations

    News

    Trials
    5ms
    Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. (clinicaltrials.gov)
    P=N/A, N=22, Not yet recruiting, Case Comprehensive Cancer Center | Trial completion date: Feb 2025 --> Sep 2025 | Trial primary completion date: Dec 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    Targretin gel (bexarotene topical)
    1year
    Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. (clinicaltrials.gov)
    P=N/A, N=22, Not yet recruiting, Case Comprehensive Cancer Center | Trial completion date: Sep 2024 --> Feb 2025 | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    Targretin gel (bexarotene topical)
    over1year
    Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. (clinicaltrials.gov)
    P=N/A, N=22, Not yet recruiting, Case Comprehensive Cancer Center | Trial primary completion date: Jul 2023 --> Jun 2024
    Trial primary completion date
    |
    Targretin gel (bexarotene topical)
    over1year
    A new case of lymphomatoid papulosis and mycosis fungoides coexistence (WCD 2023)
    LyP treatment options include topical steroids, topical bexarotene, phototherapy, nitrogen mustard, methotrexate, and intralesional interferon. In our patient, the papules and ulcerated plaques regressed under treatment with methotrexate
    Clinical
    |
    CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • IL2RA (Interleukin 2 receptor, alpha) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    TNFRSF8 expression • CD8 expression • TNFRSF8 negative
    |
    methotrexate • Targretin gel (bexarotene topical) • Valchlor (mechlorethamine gel)
    almost2years
    Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides. (PubMed, Healthcare (Basel))
    Skin directed therapy includes steroids, nitrogen mustard, bexarotene gel, phototherapy UVB, and photochemiotherapy, i.e., total skin electron radiotherapy. Systemic therapies include retinoids, bexarotene, interferon, histone deacetylase inhibitors, photopheresis, targeted immunotherapy, and cytotoxic chemotherapy. Complexity of mycosis fungoides associated with long-term chronic evolution and multiple therapy based on disease stage need a multidisciplinary team approach to be treated.
    Review • Journal • IO biomarker
    |
    CD4 (CD4 Molecule)
    |
    Targretin gel (bexarotene topical) • Valchlor (mechlorethamine gel)
    almost2years
    Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer (clinicaltrials.gov)
    P1, N=24, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Nov 2022 --> Mar 2022
    Trial completion • Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Targretin gel (bexarotene topical)
    2years
    Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer. (PubMed, Cancer Prev Res (Phila))
    Maculopapular rash at the treatment site was the most common adverse event related to study drug and resolved within a few days of discontinuation. Bexarotene was detectable in breast tissue at the 10mg daily every other day dose.
    P1 data • Journal • BRCA Biomarker
    |
    CCND1 (Cyclin D1) • BRCA (Breast cancer early onset)
    |
    HR negative • BRCA mutation
    |
    Targretin gel (bexarotene topical)
    over3years
    Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer (clinicaltrials.gov)
    P1, N=27, Active, not recruiting, National Cancer Institute (NCI) | N=40 --> 27
    Clinical • Enrollment change
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Targretin gel (bexarotene topical)
    over3years
    Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2022 --> Aug 2021
    Clinical • Enrollment closed • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Targretin gel (bexarotene topical)
    over3years
    Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer (clinicaltrials.gov)
    P1, N=40, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2021 --> Nov 2022 | Trial primary completion date: Jun 2021 --> Nov 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Targretin gel (bexarotene topical)
    4years
    Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer (clinicaltrials.gov)
    P1, N=40, Suspended, National Cancer Institute (NCI) | Trial completion date: Sep 2021 --> Jun 2021
    Clinical • Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Targretin gel (bexarotene topical)
    over4years
    Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer (clinicaltrials.gov)
    P1, N=40, Suspended, National Cancer Institute (NCI) | Trial primary completion date: Sep 2021 --> Jun 2021
    Clinical • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Targretin gel (bexarotene topical)
    over4years
    Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer (clinicaltrials.gov)
    P1, N=40, Suspended, National Cancer Institute (NCI) | Trial completion date: Aug 2020 --> Sep 2021 | Trial primary completion date: Aug 2020 --> Sep 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Targretin gel (bexarotene topical)